+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
SHUKRAPHAR SHUKRAPHAR

Shukra Pharmaceuticals Share Price

₹55.86 +0.13 (0.23%)
112.40% Gain from 52W Low

25 Sep, 2026 4:01 PM (IST)

Shukra Pharmaceuticals live price: ₹55.86. It opened at ₹58 vs previous close ₹56; intraday high/low: ₹58/₹56. The 50 & 200 DMA stand at ₹46.00/₹37.90.

Shukra Pharmaceuticals Performance

  • Today's Low
  • ₹56
  • Today's High
  • ₹58
  • 52 Week Low
  • ₹26
  • 52 Week High
  • ₹65
  • Open Price₹58
  • Previous Close₹56
  • Volume2,004,513
  • 50 DMA₹46.00
  • 100 DMA₹41.30
  • 200 DMA₹37.90

Shukra Pharmaceuticals Chart

Investment Returns

  • Over 1 Month + 26.29%
  • Over 3 Month + 89.61%
  • Over 6 Month + 68.97%
  • Over 1 Year + 62.01%

Smart Investing Starts Here Start SIP with Shukra Pharmaceuticals for Steady Growth!

Invest Now

Shukra Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 72.3
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 2,456
  • P/B Ratio
  • 23.8
  • Average True Range
  • 2.8
  • EPS
  • 0.8
  • Dividend Yield
  • 0
  • MACD Signal
  • 3.8
  • RSI
  • 66.42
  • MFI
  • 43.53

Latest Stock News Updates

Shukra Pharmaceuticals Ltd - 524632 - Closure of Trading Window

Closure of Trading Window

Shukra Pharmaceuticals Ltd - 524632 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication

Shukra Pharmaceuticals Ltd - 524632 - Corrigendum To Postal Ballot Notice

Corrigendum to Post Ballot Notice

Shukra Pharmaceuticals Financials

Shukra Pharmaceuticals Technicals

EMA & SMA

Current Price
₹55.86
+ 0.13 (0.23%)
pointer
  • Bearish Moving Average 2
  • Bullish Moving Average 14
  • 20 Day
  • ₹52.70
  • 50 Day
  • ₹46.00
  • 100 Day
  • ₹41.30
  • 200 Day
  • ₹37.90

Resistance and Support

56.39 Pivot Speed
  • R3 59.10
  • R2 58.40
  • R1 57.10
  • S1 55.20
  • S2 54.50
  • S3 53.20

Shukra Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-22 A.G.M.
2026-08-12 Quarterly Results
2026-06-10 Others Inter-alia, to consider 1. Ratification of Approval for member's resolution passed in the EGM. 2. To approve draft of notice of postal ballot. 3. Other business matters.
2026-05-07 Audited Results & Final Dividend
2026-03-16 Others Inter-alia, to consider 1. To review the performance of Non-Independent Directors and the Board as a whole. 2. To Review the performance of the Chairman of the Company. 3. Other business matters.
Date Purpose Remarks
2026-09-21 FINAL Rs.0.01 per share(1%)Final Dividend
2025-09-18 FINAL Rs.0.01 per share(1%)Final Dividend
View Shukra Pharmaceuticals Dividend History Arrow
Date Purpose Remarks
2025-03-21 Split Stock split from Rs. 10/- to Re. 1/-.
Date Purpose Remarks
2024-04-20 Bonus Bonus issue in the ratio of 3:1 of Rs. 10/-.

Shukra Pharmaceuticals Shareholding Pattern

50.96%
48.93%
0.11%

About Shukra Pharmaceuticals

Shukra Pharmaceuticals is engaged in the manufacturing, marketing, and export of pharmaceutical formulations. The Company caters to both domestic and international markets, with a growing presence in countries such as Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen. View More
  • NSE Symbol
  • SHUKRAPHAR
  • BSE Symbol
  • 524632
  • ISIN
  • INE551C01044

Similar Stocks to Shukra Pharmaceuticals

Shukra Pharmaceuticals FAQs

Shukra Pharmaceuticals share price is ₹55 As on 27 September, 2026 | 16:11

The Market Cap of Shukra Pharmaceuticals is ₹2455.7 Cr As on 27 September, 2026 | 16:11

The P/E ratio of Shukra Pharmaceuticals is 72.3 As on 27 September, 2026 | 16:11

The PB ratio of Shukra Pharmaceuticals is 23.8 As on 27 September, 2026 | 16:11

The 52 week High & Low of Shukra Pharmaceuticals is ₹65.3/₹26.3 respectively As on 27 September, 2026 | 16:11

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23